SARS-CoV-2 RBD of Spike protein, E484Q, L452R – lineage B.1.617 – Indian Kappa Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein, E484Q, L452R – lineage B.1.617 – Indian Kappa Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /SynonymsG/452R.R3, VUI-21APR-01, Lineage B.1.617, Indian variant, double mutant, kappa variant
ReferencePX-COV-P059
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein, E484Q, L452R – lineage B.1.617 – INDIAN Variant

Lineage B.1.617, also known as the Indian variant, has been named variant under investigation (VUI) by the Public Health England (PHE) at the beginning of April 2021. This variant was first reported in India at the end of March 2021 and it could be responsible for the third wave of COVID-19 in that region. However, B.1.617 may have originated much earlier because the first genome of this lineage was submitted to the global database (GISAID) as early as October 2020. Since then, the variant has shown a sustained spread across India reaching a relative abundance of 33% during April. Moreover, it has also been detected in other countries, namely in the UK and the US (February 2021) where it continues to spread unattained. This variant carries two important mutations on the receptor-binding domain (RBD) of the spike protein – E484Q and L452R. These two mutations have been previously described in other SARS-CoV-2 variants and are known to confer immune escape and to increase infectivity. Nevertheless, this is the first time the two RBD mutations are detected on the same lineage of SAR-CoV-2 which is often referred to as a “double mutant.”
The L452R amino acid change has been reported in another high-frequency lineage – B.1.429 first detected in California, US. While the amino acid change on position E484 has been reported on the South African (B.1.351), Brazilian (P.1), and NY variants (B.1.526) all shown to carry mutation E484K (instead of E484Q). Besides these mutations, B.1.617 carries 11 additional mutations that result in amino acid changes, including spike mutation P681R outside of the RBD, which is located adjacent to the furin cleavage site of the spike suggesting it might influence the way the spike is processed during infection.
Studies with B.1.617 will be crucial to understand how these mutations will affect vaccine and drug efficiency for the prevention and treatment of the COVID-19 disease.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein, E484Q, L452R – lineage B.1.617 – Indian Kappa Variant”

Your email address will not be published. Required fields are marked *

Related products

Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031-SIL 1500€
Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032-SIL 1500€
Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033-SIL 1500€
Stable Isotope Labeled Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Stable Isotope Labeled Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637-SIL 1500€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 230€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.